Head of Information Technology
Mark Yunger is the Head of Information Technology at Servier Pharmaceuticals. He works closely with R&D, Technical Operations, Commercial, and Corporate functions. He is responsible for leveraging information technology to accelerate therapies through the pipeline in our pursuit to improve patients' lives. He guides the development and partnering of the company’s digital therapeutics portfolio.
With over 20 years of technology leadership experience within the biotech and high-tech industries, Mark is a proven leader in building world class technology organizations. Prior to Servier Pharmaceuticals, Mark was Head of Information Technology for Seres Therapeutics where he led the building of foundational capabilities to advance microbiome-based products to cure infectious diseases including C. difficile and Ulcerative colitis. Mark was the Vice President of Infrastructure and Operations at Biogen where he led a team of technologists that maintained Biogen’s applications from R&D, to Pharmaceutical Operations and Technology, to Commercial as well as empowered the acceleration of Biogen's business through designing and building leading-edge cloud services and high performance computing.
Mark received his Bachelor of Science in Psychology from Western Michigan University. He earned his Master of Science in Industrial Organizational Psychology from Springfield College. He continued his education earning a Doctor of Philosophy in Labor Market and Workforce Development from Northeastern University.
To learn more about Mark connect with him on LinkedIn.
More from Servier
Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.Learn More
Servier Pharmaceuticals is an independent, privately held United States company launched by Servier Group, a unique global organization, and is governed by a non-profit foundation.Learn More
Servier has a 65-year history of helping provide innovative medicines to patients globally. In the United States, Servier intends to uphold and build upon that history.Learn More